Therapeutic Efficacy of Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors for Human Ovarian Cancer

LISA ISODA; EMIKO SONODA-FUKUDA; HIROAKI FUJINO; TORU TAKARADA; KOSEI HASEGAWA; NORIYUKI KASAHARA; SHUJI KUBO

doi:10.21873/anticanres.16734

Article Information

vol. 43 no. 12 5311-5317

DOI

https://doi.org/10.21873/anticanres.16734

PMID

38030176

Published By

International Institute of Anticancer Research

Print ISSN

0250-7005

Online ISSN

1791-7530

History

Received October 17, 2023
Revision received November 13, 2023
Accepted November 14, 2023
Published online November 29, 2023.

Copyright © 2023 The Author(s). Published by the International Institute of Anticancer Research. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

Author Information

LISA ISODA¹,²,
EMIKO SONODA-FUKUDA¹,
HIROAKI FUJINO¹,²,
TORU TAKARADA¹,³,
KOSEI HASEGAWA⁴,
NORIYUKI KASAHARA⁵ and
SHUJI KUBO¹ ⇑

¹Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Nishinomiya, Japan;
²Department of Biomedical Chemistry, School of Science and Technology, Kwansei Gakuin University, Sanda, Japan;
³Laboratory of Functional Molecular Chemistry, Kobe Pharmaceutical University, Kobe, Japan;
⁴Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Japan;
⁵Departments of Neurological Surgery and Radiation Oncology, University of California, San Francisco, CA, U.S.A.

Correspondence to: Shuji Kubo, Laboratory of Molecular and Genetic Therapeutics, Institute for Advanced Medical Sciences, Hyogo Medical University,1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan. Tel: +81 798456844, e-mail: s-kubo{at}hyo-med.ac.jp

View Full Text